RENEE FRIESNER: Open Payments
NPI 1396343422 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,156 in 56 payments from 15 companies in 2025. Trend: 2023 $536 · 2024 $1,432 · 2025 $1,156
Food & beverage: $1,156
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $335 |
| Neurocrine BioSciences, Inc. | 8 | $189 |
| Otsuka America Pharmaceutical, Inc. | 5 | $111 |
| Vanda Pharmaceuticals Inc. | 5 | $107 |
| ABBVIE INC. | 5 | $94 |
| Janssen Pharmaceuticals, Inc | 3 | $68 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Alkermes, Inc. | 1 | $25 |
Products named: CAPLYTA, INGREZZA, HETLIOZ, VRAYLAR, REXULTI, INVEGA SUSTENNA, ABILIFY ASIMTUFII, Auvelity.
Industry payments across CA — which companies pay providers there.
